Trans-Hit Biomarkers - Access To Animal Models

By: Trans-hit Biomarkers  09-12-2011
Keywords: disease, Biomarkers, Animal Models

Animal models are often critical for establishing a first and rapid proof-of-principal for a new drug candidate or a new diagnostic biomarker. Unfortunately, animal models do not always fully reflect the human pathophysiology of a given indication, leading to difficult translational research studies. Therefore, it is essential to carefully select the animal model to be employed. Use of the appropriate animal model will provide a "Go/No Go" milestone, supporting a decision to terminate or advance the project into the next development stage.

Some preclinical animal models offer the ability to identify and measure biomarkers in biological samples before and during the development of a disease (each animal is its own control), under perfectly controlled experimental conditions. Collecting similar human samples before and during disease would require long and costly prospective studies that would severely limit the advancement of research and development. When possible for animal models, an access to imaging technologies including MRI and µPET, could be very useful for correlating a given biomarker with an anatomical or functional disease-induced change.Trans-Hit Biomarkers has established partnerships with CROs which are world-renowned for their expertise in preclinical assessments and evaluation of novel therapeutic agents or biomarkers. Animal models selected for translational research ideally should allow repetitive samplings. In addition, selected preclinical CRO partners have extensive knowledge and expertise in their respective fields of specialization, offering Trans-Hit Biomarkers and its clients the ability to evaluate the pertinence of their biomarkers.

Examples of animal models available through our CRO partners:



Xenograft and Orthotopic Animal Models of Cancers, Metabolic Syndrome, Diabetes and Diabetes Complications, Atherosclerosis, Myocardial Infarction, Benign Prostratic Hypertrophy and Prostatitis, Interstitial Cystitis .. and  others

Keywords: Animal Models, Biomarkers, disease

Contact Trans-hit Biomarkers

Email - none provided

Print this page

Other products and services from Trans-hit Biomarkers

09-12-2011

Trans-Hit Biomarkers - Unique services to TTOs and their scientists developing new biomarkers and diagnostic technologies

Our expertise in helping biomarker scientists to advance their biomarkers to the market is widely recognized by many well-known TTOs and key industrial players in the biomarker domain. At Trans-Hit Biomarkers we know the challenges you face in taking your newly discovered biomarker through validation and eventually to a commercialized product.


09-12-2011

Trans-Hit Biomarkers - Regulatory Services

Based on the regulatory path that we will define for you, we can help you optimize each step of your research and development plan from concept to marketing strategy. Our corporate goal is to develop long-term relationships and commitments with our clients and to provide high-quality, comprehensive services and expert support.


09-12-2011

Trans-Hit Biomarkers - Proteome-Hit

By combining Trans-hit Biomarkers’ access to large high-quality biospecimen collections with Caprion’s high-throughput and quantitative multiplexed mass spectrometry assays, Proteome-Hit turns the usually expensive and time-consuming clinical validation route into a fast, cost-effective and robust process.


09-12-2011

Trans-Hit Biomarkers - Prospective Biobanking Services

Trans-Hit Biomarkers will take care of the selection, set-up and monitoring of investigator sites when multicenter prospective studies are needed for the clinical validation of new biomarkers, maintaining high-quality standards for biospecimen sampling, shipping and storage. Trans-Hit Biomarkers can help you decide which path is right for your clinical and regulatory plans, as well as help you to find retrospective samples to fit your needs.


09-12-2011

Trans-Hit Biomarkers - Access To Human Biospecimen Collections

Assuming sample collections are of good quality and that the scientific, legal and regulatory challenges have been overcome, sample-based research should ultimately lead to the discovery and validation of new biomarkers for predictive, prognostic, surrogate and efficacy diagnostic tests.


09-12-2011

Trans-Hit Biomarkers - ImaProteome

MALDI-Imaging Mass Spectrometry technology developed by ImaBiotech allows to generate molecular images and to quantify the distribution of molecules in complex samples such as organs, tissues and biopsies, without labeling, extraction/purification and degradation. Via automation and data processing, molecular maps of molecules can be easily generated from tissue sections collected from patients with cancer, CNS diseases, and many other diseases.